Charles Schwab
ELVN icon

Charles Schwab’s Enliven Therapeutics ELVN Stock Holding History

Charles Schwab’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5M Buy
424,440
+63,863
+18% +$2.71M ﹤0.01% 1786
2026
Q1 		$14.1M Buy
360,577
+5,385
+2% +$149K ﹤0.01% 1933
2025
Q4 		$5.47M Sell
355,192
-8,010
-2% -$160K ﹤0.01% 2407
2025
Q3 		$7.43M Buy
363,202
+57,542
+19% +$1.16M ﹤0.01% 2261
2025
Q2 		$6.13M Buy
305,660
+46,123
+18% +$873K ﹤0.01% 2247
2025
Q1 		$5.11M Sell
259,537
-2,351
-0.9% -$50.6K ﹤0.01% 2260
2024
Q4 		$5.89M Buy
261,888
+6,611
+3% +$171K ﹤0.01% 2263
2024
Q3 		$6.52M Buy
255,277
+24,043
+10% +$557K ﹤0.01% 2235
2024
Q2 		$5.4M Buy
231,234
+72,199
+45% +$1.52M ﹤0.01% 2326
2024
Q1 		$2.8M Buy
159,035
+595
+0.4% +$9.13K ﹤0.01% 2498
2023
Q4 		$2.19M Buy
158,440
+1,809
+1% +$22.1K ﹤0.01% 2589
2023
Q3 		$2.14M Buy
156,631
+94,169
+151% +$1.59M ﹤0.01% 2575
2023
Q2 		$1.27M Buy
+62,462
New +$1.26M ﹤0.01% 2684
2023
Q1 		– Sell
-2,880
Closed -$47.1K – 3562
2022
Q4 		$47.1K Buy
+2,880
New +$46K ﹤0.01% 3372
2021
Q3 		– Sell
-4,571
Closed -$145K – 3515
2021
Q2 		$145K Sell
4,571
-3,867
-46% -$120K ﹤0.01% 3280
2021
Q1 		$285K Sell
8,438
-349
-4% -$17.7K ﹤0.01% 3257
2020
Q4 		$775K Buy
8,787
+810
+10% +$68K ﹤0.01% 2850
2020
Q3 		$650K Sell
7,977
-199
-2% -$17.9K ﹤0.01% 2806
2020
Q2 		$904K Buy
+8,176
New +$915K ﹤0.01% 2653

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Charles Schwab's ELVN Position: Q2 2026 in Review

Charles Schwab increased its Enliven Therapeutics (ELVN) stake by 18% in Q2 2026, buying an estimated $2.71M and bringing the position to 424,440 shares worth $21.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1786.

Charles Schwab first reported a position in ELVN in Q2 2020 and has held it in 19 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Charles Schwab held 424,440 shares of Enliven Therapeutics worth $21.5M as of Q2 2026.
  • Charles Schwab bought 63,863 Enliven Therapeutics shares in Q2 2026, an estimated $2.71M.
  • Enliven Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1786 holding.
  • Charles Schwab first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 19 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.